Tatva Chintan

Why is Tatva Chintan Pharma Chem Ltd falling/rising?

As of 14-Jun, Tatva Chintan Pharma Chem Ltd's stock price is rising to 1,204.25, with a 4.4% increase and strong investor interest reflected in higher delivery volumes. Positive financial results, including a 2.14% growth in net sales, have contributed to this upward trend despite some long-term concerns.

As of 14-Jun, Tatva Chintan Pharma Chem Ltd's stock price is rising, currently at 1,204.25, reflecting a change of 50.7 (4.4%) upward. The stock has outperformed its sector by 3.36% today and has shown consecutive gains over the last two days, accumulating a total return of 9.01% in this period. The stock reached an intraday high of Rs 1214, marking a 5.24% increase.<BR><BR>Investor participation has also increased, with a delivery volume of 19.35k on June 11, which is an 8.46% rise compared to the 5-day average delivery volume. This indicates growing interest and confidence among investors. Additionally, the company has reported positive financial results, including a 2.14% growth in net sales and the highest quarterly net sales at Rs 134.14 crore, which has contributed to the stock's upward movement.<BR><BR>Despite some long-term concerns regarding growth and institutional investor participation, the stock's recent performance and positive quarterly results have driven its current rise.

Which are the latest news on Tatva Chintan?

What does Tatva Chintan do?

Tatva Chintan Pharma Chem Ltd is a small-cap company in the specialty chemicals industry, incorporated in 1996 and publicly listed since January 2021, with recent net sales of 134 Cr and a net profit of 10 Cr as of March 2026. Key financial metrics include a P/E ratio of 62.00 and a market cap of INR 2,710 Cr.

Overview:<BR>Tatva Chintan Pharma Chem Ltd operates in the specialty chemicals industry and is categorized as a small-cap company.<BR><BR>History:<BR>Tatva Chintan Pharma Chem Limited was incorporated in 1996 as 'Tatva Chintan Pharma Chem Private Limited' and transitioned to a public limited company on 27 January 2021. The latest quarterly results report net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 134 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 10 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 2,710 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 62.00 <BR>Industry P/E: 42 <BR>Dividend Yield: 0.09% <BR>Debt-Equity: 0.14 <BR>Return on Equity: 5.38% <BR>Price to Book: 3.47 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Tatva Chintan?

As of 10th June, Tatva Chintan Pharma Chem Ltd has a market capitalization of 2,710.00 Cr, with recent Net Sales of 505.85 Cr and a Net Profit of 42.06 Cr.

As of 10th June, Tatva Chintan Pharma Chem Ltd has a market capitalization of 2,710.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 505.85 Cr and a Net Profit of 42.06 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 738.82 Cr and Total Assets of 823.62 Cr.

Who are in the management team of Tatva Chintan?

The management team of Tatva Chintan includes Chintan Nitinkumar Shah (Chairman/Executive Director), Ajaykumar Mansukhlal Patel, Shekhar Rasiklal Somani (both Whole-Time Directors/Executive Directors), and independent directors Subhash Patel, Avani Rajesh Umatt, and Manher Chinmanlal Desai. They oversee the company's strategic direction and operations.

The management team of Tatva Chintan includes the following members:<BR><BR>1. **Chintan Nitinkumar Shah** - Chairman / Executive Director<BR>2. **Ajaykumar Mansukhlal Patel** - Whole-Time Director & Executive Director<BR>3. **Shekhar Rasiklal Somani** - Whole-Time Director & Executive Director<BR>4. **Subhash Patel** - Independent Non-Executive Director<BR>5. **Avani Rajesh Umatt** - Independent Non-Executive Director<BR>6. **Manher Chinmanlal Desai** - Independent Non-Executive Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Who are the peers of the Tatva Chintan?

Tatva Chintan's peers include Vishnu Chemicals, Styrenix Perfor., Foseco India, Yasho Industries, Rossari Biotech, Jubilant Agri, NOCIL, DDev Plastiks, and Camlin Fine. Management risk varies from excellent to below average among these companies, with Tatva Chintan showing average growth and capital structure.

Peers: The peers of Tatva Chintan are Vishnu Chemicals, Styrenix Perfor., Foseco India, Yasho Industries, Rossari Biotech, Jubilant Agri, NOCIL, DDev Plastiks, and Camlin Fine.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vishnu Chemicals, Styrenix Perfor., Rossari Biotech, and Jubilant Agri, while Average management risk is found at Foseco India, Yasho Industries, NOCIL, Tatva Chintan, DDev Plastiks, and Bhansali Engg. Below Average management risk is noted at Camlin Fine. Growth is Excellent at Jubilant Agri, Good at Vishnu Chemicals, Foseco India, Yasho Industries, and DDev Plastiks, while Average growth is seen at Rossari Biotech and Tatva Chintan. Below Average growth is reported for Styrenix Perfor., Yasho Industries, NOCIL, and Camlin Fine. Capital Structure is Excellent at Styrenix Perfor., Foseco India, Rossari Biotech, Jubilant Agri, NOCIL, DDev Plastiks, and Bhansali Engg., while Average is noted for Vishnu Chemicals and Tatva Chintan, and Below Average for Yasho Industries and Camlin Fine.<BR><BR>Return Snapshot: Yasho Industries has the highest 1-year return at 25.06%, while Camlin Fine has the lowest at -57.48%. Tatva Chintan's 1-year return of 19.49% is higher than that of Camlin Fine but lower than Yasho Industries. Additionally, the six-month return is negative for Rossari Biotech, Jubilant Agri, NOCIL, DDev Plastiks, and Camlin Fine.

Should I buy, sell or hold Tatva Chintan Pharma Chem Ltd?

Are Tatva Chintan Pharma Chem Ltd latest results good or bad?

Tatva Chintan Pharma Chem Ltd's latest results show a significant year-on-year net profit increase of 901.94% and a 24.36% revenue growth, indicating recovery; however, there was a 31.97% decline in net profit quarter-on-quarter due to a high tax rate, raising concerns about sustainable profitability despite operational momentum.

Tatva Chintan Pharma Chem Ltd's latest results present a mixed picture. On one hand, the company reported a significant year-on-year increase in net profit, soaring by 901.94% to ₹10.32 crores in Q4 FY26. This reflects a recovery from a challenging previous year. Additionally, revenue grew by 24.36% year-on-year, reaching ₹134.14 crores, marking the highest level in at least eight quarters.<BR><BR>However, the quarter-on-quarter performance reveals a concerning decline, with net profit dropping by 31.97% from ₹15.17 crores in Q3 FY26. This decline was primarily attributed to an unusually high effective tax rate of 37.79%, which significantly impacted profitability. Moreover, while operating margins improved to 20.97%, they remain below the levels seen in previous quarters.<BR><BR>The company has demonstrated operational momentum with seven consecutive quarters of revenue growth, but the volatility in profit margins and the low return on equity of 5.83% compared to industry peers raises questions about sustainable profitability. Overall, while there are positive signs of recovery, the recent results also highlight significant challenges that need to be addressed for long-term stability and growth.

When is the next results date for Tatva Chintan Pharma Chem Ltd?

The next results date for Tatva Chintan Pharma Chem Ltd is 16 May 2026.

The next results date for Tatva Chintan Pharma Chem Ltd is scheduled for 16 May 2026.

How has been the historical performance of Tatva Chintan?

Tatva Chintan's historical performance has shown significant volatility, with net sales and profits declining from 2022 to 2025, while total assets and liabilities increased. Key metrics include a drop in profit after tax from INR 95.87 crore in March 2022 to INR 5.71 crore in March 2025.

Answer:<BR>The historical performance of Tatva Chintan shows a fluctuating trend in key financial metrics over the years.<BR><BR>Breakdown:<BR>Tatva Chintan's net sales have seen a decline from INR 423.61 crore in March 2023 to INR 382.71 crore in March 2025, with a peak of INR 433.65 crore in March 2022. Total operating income followed a similar trend, decreasing to INR 382.71 crore in March 2025 from INR 423.61 crore in March 2023. The company's operating profit (PBDIT) also dropped significantly from INR 117.26 crore in March 2022 to INR 36.53 crore in March 2025. Profit before tax decreased from INR 104.12 crore in March 2022 to INR 7.58 crore in March 2025, while profit after tax fell from INR 95.87 crore in March 2022 to INR 5.71 crore in March 2025. The earnings per share (EPS) reflected this decline, dropping from INR 43.24 in March 2022 to INR 2.44 in March 2025. On the balance sheet, total assets increased from INR 649.59 crore in March 2022 to INR 823.62 crore in March 2025, while total liabilities also rose from INR 649.59 crore to INR 823.62 crore in the same period. Cash flow from operating activities decreased from INR 98 crore in March 2024 to INR 24 crore in March 2025, and the company experienced a net cash outflow of INR 23 crore in March 2025. Overall, Tatva Chintan's financial performance has shown significant volatility, particularly in profitability metrics, while total assets and liabilities have increased.

Is Tatva Chintan technically bullish or bearish?

As of 14 October 2025, Tatva Chintan's technical trend is bullish, supported by strong daily moving averages and positive Bollinger Bands and OBV, although caution is advised due to mildly bearish signals from the MACD and KST on the weekly chart.

As of 14 October 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish, with strength indicated by daily moving averages and positive performance in the Bollinger Bands and OBV on both weekly and monthly time frames. However, the MACD and KST on the weekly show mildly bearish signals, which suggests some caution. Overall, the bullish indicators outweigh the bearish ones, supporting a positive outlook for Tatva Chintan in the specialty chemicals industry.

Who are the top shareholders of the Tatva Chintan?

The top shareholders of Tatva Chintan include Shekhar Rasiklal Somani with 23.07%, two mutual fund schemes with 5.34%, 15 foreign institutional investors holding 3.3%, and Nippon Life India Trustee Ltd at 3.31%, while individual investors account for 16.92%.

The top shareholders of Tatva Chintan include the promoters, with Shekhar Rasiklal Somani holding the highest stake at 23.07%. There are also two mutual fund schemes that collectively hold 5.34%, and 15 foreign institutional investors (FIIs) with a combined holding of 3.3%. Additionally, the highest public shareholder is Nippon Life India Trustee Ltd, which holds 3.31%. Individual investors account for 16.92% of the shareholding.

Is Tatva Chintan overvalued or undervalued?

As of August 18, 2021, Tatva Chintan is considered overvalued with a PE ratio of 379.10, significantly higher than its peers, and despite short-term gains, it has a poor long-term performance with a 3-year return of -59.09%.

As of 18 August 2021, the valuation grade for Tatva Chintan moved from does not qualify to very expensive, indicating a significant shift in its perceived market value. The company is currently assessed as overvalued, with a PE ratio of 379.10, an EV to EBITDA ratio of 64.04, and a Price to Book Value of 2.94. These ratios suggest that the stock is trading at a premium compared to its earnings and book value, raising concerns about its sustainability at such high valuations.<BR><BR>In comparison to its peers, Tatva Chintan's valuation appears excessive, particularly when contrasted with Solar Industries India Ltd., which has a PE ratio of 123.77, and Godrej Industries Ltd., which is valued at a much more reasonable PE of 46.63. The stark differences in these ratios highlight the relative overvaluation of Tatva Chintan within the specialty chemicals sector. Furthermore, while the company has outperformed the Sensex in the short term, with a 1-month return of 30.59% compared to the Sensex's 3.81%, its long-term performance has been lackluster, with a 3-year return of -59.09%. This discrepancy reinforces the conclusion that Tatva Chintan is currently overvalued.

Has Tatva Chintan declared dividend?

Tatva Chintan Pharma Chem Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of September 6, 2024. Despite the dividend announcement, the company has experienced significant declines in price returns over various periods.

Tatva Chintan Pharma Chem Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 06 Sep 24<BR><BR>Dividend Yield: 0.21%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 4.34%, the dividend return was 0%, resulting in a total return of 4.34%.<BR><BR>Over the past year, the price return was -8.59%, with a dividend return of 0.20%, leading to a total return of -8.39%.<BR><BR>In the last 2 years, the price return was -43.71%, while the dividend return was 0.23%, resulting in a total return of -43.48%.<BR><BR>For the 3-year period, the price return was -60.51%, the dividend return was 0.28%, culminating in a total return of -60.23%.<BR><BR>Over the last 4 years, there was no price return and no dividend return, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there was also no price return and no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Tatva Chintan has declared a dividend, the total returns over various periods indicate significant declines in price, suggesting challenges in the company's performance despite the dividend announcement.